Prasugrel during primary percutaneous coronary intervention: evidence from clinical data
Giuseppe Biondi-Zoccai1, Antonio Abbate, Fabrizio D'Ascenzo
1Division of Cardiology, University of Modena and Reggio Emilia, Via Del Pozzo 71, Modena, Italy. gbiondizoccai@gmail.com
Current Vascular Pharmacology
|February 21, 2012
Summary
Dual antiplatelet therapy is crucial after percutaneous coronary intervention for ST-elevation myocardial infarction (STEMI). Newer agents like prasugrel offer potent antithrombotic effects but increase bleeding risk, necessitating individualized treatment decisions.
Area of Science:
- Cardiology
- Interventional Cardiology
- Pharmacology
Background:
- Primary percutaneous coronary intervention (PCI) with stent implantation is standard for ST-elevation myocardial infarction (STEMI).
- Antithrombotic therapy is vital post-PCI to prevent thrombotic events while managing bleeding risk.
- Aspirin and clopidogrel were the standard oral antiplatelet therapy.
Purpose of the Study:
- To evaluate the role of novel antithrombotic agents in STEMI management.
- To compare the efficacy and safety of prasugrel versus traditional therapies.
- To inform individualized antithrombotic treatment strategies.
Main Methods:
- Review of randomized trials evaluating prasugrel in STEMI patients undergoing PCI.
- Analysis of antithrombotic efficacy and bleeding risk associated with prasugrel, clopidogrel, and ticagrelor.
- Assessment of patient-specific factors influencing treatment decisions.
Main Results:
- Prasugrel demonstrates potent antithrombotic effects in STEMI patients.
- Prasugrel is associated with a statistically significant increase in bleeding risk.
- Increased bleeding risk with prasugrel is noted in elderly, low-body-weight, and stroke/TIA patients.
Conclusions:
- Individualized selection of antithrombotic therapy (prasugrel, clopidogrel, ticagrelor) is essential for STEMI patients undergoing PCI.
- Balancing potent antithrombotic benefits against increased bleeding hazards is critical.
- Patient-specific factors must guide the choice of antiplatelet agent to optimize outcomes.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:30Acute Coronary Syndrome III: Diagnostic Studies
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
01:30Acute Coronary Syndrome I: Introduction
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
01:27Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
01:28Acute Coronary Syndrome IV: Interprofessional Care
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...